Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 9,963 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCH Clear all
Completed Phase 2Phase 3 Interventional Results available

Trial in Adult Participants With Spinocerebellar Ataxia (SCA)

NCT02960893
View directory record Official record
Conditions
Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6, Spinocerebellar Ataxia Genotype Type 7, Spinocerebellar Ataxia Genotype Type 8, Spinocerebellar Ataxia Genotype Type 10
Interventions
Troriluzole, Placebo
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Long Beach, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

NCT05090904
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Brensocatib, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
14
States / cities
Gainesville, Florida • Augusta, Georgia • Glenview, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

NCT01691521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

Effects of Atomoxetine in Mild Cognitive Impairment

NCT01522404
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
Atomoxetine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 21, 2026, 9:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis

NCT00930384
View directory record Official record
Conditions
Psoriasis, Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

NCT02122471
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
167
States / cities
Anniston, Alabama • Huntsville, Alabama • Chandler, Arizona + 119 more
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Not applicable Interventional Results available

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

NCT01755455
View directory record Official record
Conditions
Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions
Ferrous sulfate 325mg, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Portland, Maine • Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 2Phase 3 Interventional

Phase 2b/3 Study to Assess ABP-671 a Novel URAT1 Inhibitor in Participants With Gout

NCT05818085
View directory record Official record
Conditions
Gout
Interventions
ABP-671, Allopurinol, Placebo
Drug · Other
Lead sponsor
Atom Therapeutics Co., Ltd
Industry
Eligibility
19 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
35
States / cities
Tempe, Arizona • Tuscon, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544763
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Seizures
Interventions
GWP42003-P, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
1 Year to 65 Years
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
23
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 3 Interventional

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

NCT05517421
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
Batoclimab, Placebo
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
29
States / cities
Beverly Hills, California • Carlsbad, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 21, 2026, 9:03 AM EDT
Active, not recruiting Phase 1 Interventional

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO)

NCT02050347
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL
Interventions
CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T Cells - dose escalation 1
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 2 Interventional

Allopurinol Combination Study

NCT01001338
View directory record Official record
Conditions
Gout
Interventions
RDEA594, Placebo, Allopurinol
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 21, 2026, 9:03 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Pilot of Reconnecting to Internal Sensations and Experiences in Undergraduates

NCT05285111
View directory record Official record
Conditions
Suicidal Ideation, Eating Disorder Symptom
Interventions
Reconnecting to Internal Sensations and Experiences, Healthy Habits
Behavioral
Lead sponsor
Auburn University
Other
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Auburn, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 21, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional

Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder

NCT03430544
View directory record Official record
Conditions
Cocaine Use Disorder
Interventions
Cariprazine Oral Capsule [Vraylar], Placebo oral capsule
Drug
Lead sponsor
Anna Rose Childress, Ph.D.
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 3 Interventional Results available

Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses

NCT02952898
View directory record Official record
Conditions
Actinic Keratosis
Interventions
GDC 695, Diclofenac Sodium Gel, 3%, Vehicle gel
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fort Smith, Arkansas • San Diego, California • San Ramon, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 21, 2026, 9:03 AM EDT
Recruiting Phase 3 Interventional

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

NCT07750158
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo
Drug · Biological
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
13
States / cities
Council Bluffs, Iowa • Grand Island, Nebraska • Omaha, Nebraska + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Fostamatinib in Subjects With Impaired Hepatic (Liver) Function

NCT01222455
View directory record Official record
Conditions
Hepatic Impairment, Healthy Volunteers, Pharmacokinetics, Amount of R406 in Blood
Interventions
Fostamatinib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 6, 2011 · Synced Oct 21, 2026, 9:03 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

NCT00455429
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate the Effect of Ulonivirine (MK-8507) on Heart Rhythm in Healthy Adults (MK-8507-012)

NCT07305831
View directory record Official record
Conditions
Healthy
Interventions
Ulonivirine, Moxifloxacin, Ulonivirine Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 21, 2026, 9:03 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047

NCT03160339
View directory record Official record
Conditions
Adenoviral Infection
Interventions
PXVX0047 Vaccine, Teva Ad4/Ad7 Vaccine
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 35 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
2
States / cities
Cincinnati, Ohio • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 21, 2026, 9:03 AM EDT
Recruiting Early Phase 1 Interventional

GWICTIC: NAC Mechanistic Study in Gulf War Veterans

NCT04987775
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
Nova Southeastern University
Other
Eligibility
47 Years to 70 Years
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Palo Alto, California • Fort Lauderdale, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 21, 2026, 9:03 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effect of GRF6021 on Postoperative Recovery Following Primary Hip or Knee Arthroplasty

NCT03981419
View directory record Official record
Conditions
Postoperative Recovery
Interventions
GRF6021, Placebo
Biological · Other
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 21, 2026, 9:03 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Is Cognitive Training Neuroprotective in Early Psychosis?

NCT03049800
View directory record Official record
Conditions
Psychosis, Healthy
Interventions
Magnetic Resonance Imaging
Device
Lead sponsor
University of Minnesota
Other
Eligibility
16 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 21, 2026, 9:03 AM EDT